---
title: "Hansoh Pharma Wins NMPA Breakthrough Status for Fourth-Gen Lung Cancer Drug"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287208778.md"
description: "Hansoh Pharmaceutical Group has received breakthrough-therapy designation from China's NMPA for its fourth-generation lung cancer drug HS-10504, aimed at patients with specific EGFR mutations. This designation is expected to expedite the drug's development and regulatory review, enhancing Hansoh's position in the oncology market. Analysts rate the stock as a Buy with a target price of HK$47.00."
datetime: "2026-05-21T11:13:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287208778.md)
  - [en](https://longbridge.com/en/news/287208778.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287208778.md)
---

# Hansoh Pharma Wins NMPA Breakthrough Status for Fourth-Gen Lung Cancer Drug

### Meet Samuel – Your Personal Investing Prophet

-   Start a conversation with TipRanks’ trusted, data-backed investment intelligence
-   Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds

Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) has issued an update.

Hansoh Pharmaceutical Group has secured breakthrough-therapy designation from China’s National Medical Products Administration for HS-10504, its self-developed fourth-generation EGFR tyrosine kinase inhibitor. The oral therapy is proposed for patients with locally advanced or metastatic non-small cell lung cancer carrying the EGFR C797S mutation following failure of prior EGFR-TKI treatment.

The designation is expected to accelerate the development and regulatory review of HS-10504, underscoring Hansoh’s push into next-generation targeted lung cancer therapies. It also reinforces the company’s positioning in China’s competitive oncology drug market by addressing a hard-to-treat patient segment with limited existing options.

The most recent analyst rating on (HK:3692) stock is a Buy with a HK$47.00 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.

**More about Hansoh Pharmaceutical Group Company Limited**

Hansoh Pharmaceutical Group Company Limited is a China-based biopharmaceutical company focused on the research, development and commercialization of innovative therapies. The group develops small-molecule drugs and other treatments targeting major diseases, with a growing oncology portfolio aimed at lung cancer and other high-incidence conditions in the domestic market.

**Average Trading Volume:** 9,584,812

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$203.8B

For an in-depth examination of 3692 stock, go to TipRanks’ Overview page.

### Related Stocks

- [03692.HK](https://longbridge.com/en/quote/03692.HK.md)

## Related News & Research

- [Hansoh Pharma Wins NMPA Nod for Trial of New KRAS-Targeting Cancer Drug](https://longbridge.com/en/news/286266501.md)
- [Hansoh Pharmaceutical Wins Breakthrough Therapy Status for Esophageal Cancer ADC](https://longbridge.com/en/news/285857826.md)
- [Bergman: ‘The time is now’ to push for breakthroughs in psychedelic treatments](https://longbridge.com/en/news/286946328.md)
- [US working with small biotech firm on experimental Ebola treatment, Bloomberg News reports](https://longbridge.com/en/news/287108072.md)
- [KOALA trial opens to enrol patients for first‑in‑human KMCAR T‑cell therapy](https://longbridge.com/en/news/287059695.md)